Halozyme Therapeutics Inc. is a biopharmaceutical company. The Company�s research focuses on human enzymes that alter the extracellular matrix. The Company�s proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter) and Intrexon Corporation (Intrexon), with approximately two approved products for marketing in Europe. The Company�s products include Hylenex Recombinant, Ultrafast Insulin Program, PEGPH20 and HTI-501.